Tejon Ranch Co.
NYSE:TRCConglomerates
-$0.06 today
- Market cap
- $465.26M
- Beta
- 0.59
- P/E (TTM)
- 296.5
- EPS (TTM)
- $0.06
Volume 0.26M
Average 0.09M
TRC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Tejon Ranch Co.NYSE: TRC
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $8.75M rose 7.5% year over year, behind the +12.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 47.8% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.
Context
- Cost of revenue amounted to 87.7% of revenue in FY2025, down 7.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +7.5% toward the trailing-twelve-month pace of +12.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 43.48M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- -1.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.48M | +8.7% |
| FY2024 | 2024-12-31 | 39.99M | +3.7% |
| FY2023 | 2023-12-31 | 38.57M | -30.9% |
| FY2022 | 2022-12-31 | 55.79M | +21.2% |
| FY2021 | 2021-12-31 | 46.03M | — |
Cost of Revenue vs competitors
How TRC compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.4% is the 3rd highest of 9, against a peer median of +6.1%.
- Cost of revenue amounts to 86.6% of revenue for TRC, versus a peer median of 76.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $1.39B USD | -6.4% | -5.7% | 89.9% | |
| LTM Mar 2026 | $1.04B USD | -7.9% | +1.3% | 56.3% | |
| LTM Mar 2026 | $792.89M USD | +13.5% | +1.0% | 93.8% | |
| LTM Mar 2026 | $771.43M USD | +6.3% | +2.3% | 87.7% | |
| LTM Apr 2026 | $382.74M USD | +10.2% | +5.6% | 73.1% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $202.09M USD | +6.0% | +8.6% | 79.5% |
| LTM Mar 2026 | $78.9M USD | -6.5% | +6.8% | 34.7% | |
| LTM Mar 2026 | $44.09M USD | +12.4% | -8.0% | 86.6% | |
| LTM Mar 2026 | £15.22M GBP | — | -10.7% | — | |
| LTM Mar 2026 | $6.4M USD | +5463.5% | -27.6% | 34.5% | |
| Peer median (excluding TRC) | — | +6.1% | +1.3% | 76.3% | |
Competitors are the stored peer set for TRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.61M | 79.22M | 44.74M | 41.89M | 49.59M |
| Cost of Revenue | 46.03M | 55.79M | 38.57M | 39.99M | 43.48M |
| Gross Profit | 9.58M | 23.43M | 6.17M | 1.89M | 6.11M |
| Gross Margin | 17.2% | 29.6% | 13.8% | 4.5% | 12.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 9.84M | 9.7M | 0 | 11.09M | 0 |
| Operating Expenses | 9.84M | 9.7M | 9.87M | 11.09M | 14.07M |
| Depreciation & Amortization | 4.59M | 4.63M | 4.81M | 4.89M | 6.01M |
| EBITDA | 13.76M | 27.83M | 10.39M | 8.55M | 7.17M |
| EBITDA Margin | 24.7% | 35.1% | 23.2% | 20.4% | 14.5% |
| Operating Income | (260K) | 13.73M | (3.7M) | (9.2M) | (7.95M) |
| Operating Margin | -0.5% | 17.3% | -8.3% | -22.0% | -16.0% |
| Interest Income | 0 | 0 | 0 | 2.27M | 914K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.42M | 9.47M | 9.29M | 12.86M | 9.11M |
| Income Before Tax | 9.16M | 23.2M | 5.59M | 3.66M | 1.16M |
| Pre-Tax Margin | 16.5% | 29.3% | 12.5% | 8.7% | 2.3% |
| Income Tax Expense | 3.82M | 7.39M | 2.32M | 976K | 1.09M |
| Net Income | 5.35M | 15.81M | 3.27M | 2.69M | 75K |
| Net Margin | 9.6% | 20.0% | 7.3% | 6.4% | 0.2% |
| EPS (Basic) | 0.20 | 0.60 | 0.12 | 0.10 | 0.00 |
| EPS (Diluted) | 0.20 | 0.59 | 0.12 | 0.10 | 0.00 |
| Weighted Avg Shares | 26.34M | 26.48M | 26.71M | 26.81M | 26.95M |
| Weighted Avg Shares (Diluted) | 26.41M | 26.65M | 26.71M | 26.82M | 26.95M |
Tejon Ranch Co.
NYSE:TRC
Intrinsic Alpha fair value
Locked
Current Price
$17.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.